IBB
$209.54-0.95%
as of close, Oct 22, 2026
☾ AH $209.54 -0.95%
iShares Biotechnology ETFETF · Themes
IBB holdings (2026)
Holdings as of Jun 30, 2026, the fund’s latest SEC filing; weights are ChartRow estimates at today’s prices.
Holdings 247 · Top 10 50% · Largest AMGN 8.8% · Median P/E 33.3 · Yield 0.45% · Avg cap $76B
Top 10 holdings#
CompanyWeight1D
7Argenx SE
3.4%—
Sector weights#
Sectors · Healthcare 85.3% · Industrials 1.0% · all 4
- Healthcare 85.3%
- Not on ChartRow 13.2%
- Industrials 1.0%
- Technology 0.5%
IBB holdings by weight#
1–100 of 247View
Table
Weightsthe Jun 30, 2026 filing rolled forward on price — an estimate (as of market close, Oct 22, 2026)
Columns & filters6 cols
Weights1–100 of 247the Jun 30, 2026 filing rolled forward on price — an estimate (as of market close, Oct 22, 2026)
Columns
| Company | ||||||
|---|---|---|---|---|---|---|
| AMGNAmgen | 8.76% | $447.28 | +2.04% | +39.4% | ||
| VRTXVertex Pharmaceuticals | 7.84% | $535.17 | +2.03% | +18.0% | ||
| GILDGilead Sciences | 7.70% | $157.19 | +2.36% | +30.4% | ||
| REGNRegeneron Pharmaceuticals | 5.79% | $819.09 | +1.67% | +6.5% | ||
| MRNAModerna | 5.12% | $202.63 | -17.57% | +587.1% | ||
| NTRANatera | 3.87% | $401.37 | -2.91% | +75.2% | ||
| Argenx SE | 3.40% | — | — | — | ||
| ILMNIllumina | 2.87% | $269.40 | -4.76% | +105.4% | ||
| BIIBBiogen | 2.61% | $253.84 | +5.34% | +44.2% | ||
| RVMDRevolution Medicines | 2.52% | $187.69 | -3.39% | +135.6% | ||
| ALNYAlnylam Pharmaceuticals | 2.13% | $227.28 | +0.97% | -42.8% | ||
| UTHRUnited Therapeutics | 1.69% | $584.79 | +3.78% | +20.0% | ||
| INCYIncyte | 1.62% | $116.93 | +3.08% | +18.4% | ||
| BeOne Medicines Ltd. | 1.60% | — | — | — | ||
| INSMInsmed | 1.44% | $95.06 | +1.08% | -45.4% | ||
| ROIVRoivant Sciences | 1.37% | $37.45 | +1.77% | +72.6% | ||
| CRLCharles River Laboratories | 1.16% | $339.66 | -1.51% | +70.3% | ||
| EXELExelixis | 1.12% | $65.31 | +1.13% | +49.0% | ||
| MEDPMedpace Holdings | 1.06% | $653.96 | -1.29% | +16.4% | ||
| ASNDAscendis Pharma | 1.06% | $242.99 | +1.71% | +14.0% | ||
| HALOHalozyme Therapeutics | 1.03% | $124.54 | -0.23% | +85.1% | ||
| Genmab A/S | 1.01% | — | — | — | ||
| NBIXNeurocrine Biosciences | 1.00% | $143.29 | +1.40% | +1.0% | ||
| BBIOBridgeBio Pharma | 0.81% | $68.12 | +0.56% | -10.9% | ||
| TECHBio-Techne | 0.80% | $72.62 | -0.03% | +24.0% | ||
| BMRNBioMarin Pharmaceutical | 0.76% | $56.63 | +2.57% | -4.7% | ||
| MDGLMadrigal Pharmaceuticals | 0.69% | $453.34 | -1.01% | -22.2% | ||
| RGENRepligen | 0.67% | $178.71 | -0.72% | +9.1% | ||
| PCVXVaxcyte | 0.63% | $62.85 | -0.60% | +36.2% | ||
| Abivax SA | 0.61% | — | — | — | ||
| PTGXProtagonist Therapeutics | 0.60% | $139.53 | +1.05% | +59.8% | ||
| BioNTech SE | 0.60% | — | — | — | ||
| KRYSKrystal Biotech | 0.58% | $320.13 | -0.63% | +29.8% | ||
| TWSTTwist Bioscience | 0.57% | $135.47 | -9.16% | +327.1% | ||
| KYMRKymera Therapeutics | 0.56% | $110.85 | -1.58% | +42.5% | ||
| TXG10x Genomics | 0.56% | $69.75 | -7.73% | +327.7% | ||
| ARWRArrowhead Pharmaceuticals | 0.55% | $58.36 | -0.82% | -12.1% | ||
| Apogee Therapeutics, Inc. | 0.53% | — | — | — | ||
| CYTKCytokinetics | 0.52% | $62.33 | -0.84% | -1.9% | ||
| ALKSAlkermes | 0.51% | $44.18 | +1.61% | +57.9% | ||
| SYRESpyre Therapeutics | 0.50% | $92.33 | -0.67% | +181.8% | ||
| IONSIonis Pharmaceuticals | 0.50% | $43.91 | -0.81% | -44.5% | ||
| PRAXPraxis Precision Medicines | 0.48% | $258.92 | +0.96% | -12.2% | ||
| TEMTempus AI | 0.48% | $63.81 | -5.83% | +8.1% | ||
| AXSMAxsome Therapeutics | 0.47% | $156.07 | -0.15% | -14.5% | ||
| Nuvalent, Inc. | 0.46% | — | — | — | ||
| BRKRBruker | 0.45% | $57.31 | -3.05% | +22.0% | ||
| RYTMRhythm Pharmaceuticals | 0.43% | $90.90 | +2.57% | -15.1% | ||
| IOVAIovance Biotherapeutics | 0.39% | $14.14 | -3.28% | +417.9% | ||
| PTCTPTC Therapeutics | 0.36% | $63.04 | +0.67% | -17.0% | ||
| GRALGRAIL | 0.36% | $127.06 | -4.18% | +48.5% | ||
| KODKodiak Sciences | 0.35% | $85.78 | -2.21% | +206.8% | ||
| TVTXTravere Therapeutics | 0.33% | $52.43 | -0.29% | +37.2% | ||
| COGTCogent Biosciences | 0.33% | $31.31 | -0.38% | -11.9% | ||
| CRSPCRISPR Therapeutics | 0.32% | $49.99 | -1.01% | -4.7% | ||
| Legend Biotech Corp. | 0.30% | — | — | — | ||
| MIRMMirum Pharmaceuticals | 0.29% | $83.10 | -0.41% | +5.2% | ||
| ORKAOruka Therapeutics | 0.29% | $81.15 | +1.54% | +167.7% | ||
| SRRKScholar Rock Holding | 0.29% | $41.96 | -2.42% | -4.7% | ||
| CAICaris Life Sciences | 0.27% | $31.71 | -1.98% | +17.5% | ||
| DFTXDefinium Therapeutics | 0.27% | $36.00 | +1.44% | +168.9% | ||
| ADPTAdaptive Biotechnologies | 0.27% | $24.41 | -3.63% | +50.3% | ||
| Crinetics Pharmaceuticals, Inc. | 0.26% | — | — | — | ||
| CGONCG Oncology | 0.25% | $62.54 | +0.48% | +50.6% | ||
| VCYTVeracyte | 0.25% | $46.04 | -0.39% | +9.4% | ||
| ARQTArcutis Biotherapeutics | 0.25% | $32.20 | +1.04% | +10.9% | ||
| ACADACADIA Pharmaceuticals | 0.24% | $20.31 | +0.59% | -24.0% | ||
| XENEXenon Pharmaceuticals | 0.23% | $36.50 | +1.53% | -18.6% | ||
| CDNACareDx | 0.23% | $69.16 | -2.23% | +267.1% | ||
| EWTXEdgewise Therapeutics | 0.22% | $39.99 | +0.86% | +61.2% | ||
| Structure Therapeutics, Inc. | 0.22% | — | — | — | ||
| IBRXImmunityBio | 0.22% | $8.31 | -3.82% | +319.7% | ||
| IDYAIDEAYA Biosciences | 0.21% | $36.12 | +1.83% | +4.5% | ||
| TNGXTango Therapeutics | 0.21% | $27.93 | +3.52% | +215.2% | ||
| TARSTarsus Pharmaceuticals | 0.21% | $72.08 | +2.24% | -12.0% | ||
| DNLIDenali Therapeutics | 0.20% | $18.66 | -0.11% | +13.0% | ||
| Newamsterdam Pharma Co. NV | 0.19% | — | — | — | ||
| ABCLAbCellera Biologics | 0.19% | $11.37 | -7.11% | +232.5% | ||
| AMLXAmylyx Pharmaceuticals | 0.19% | $28.57 | -1.58% | +136.5% | ||
| RLAYRelay Therapeutics | 0.19% | $18.34 | -0.38% | +116.8% | ||
| ERASErasca | 0.19% | $14.04 | -3.11% | +277.4% | ||
| uniQure NV | 0.18% | — | — | — | ||
| NRIXNurix Therapeutics | 0.18% | $25.51 | -1.96% | +34.5% | ||
| ADMAADMA Biologics | 0.17% | $10.95 | -0.55% | -40.0% | ||
| Alumis, Inc. | 0.17% | — | — | — | ||
| IMVTImmunovant | 0.17% | $29.10 | +2.54% | +14.5% | ||
| BEAMBeam Therapeutics | 0.16% | $24.56 | -1.13% | -11.4% | ||
| FTREFortrea Holdings | 0.16% | $23.92 | -0.58% | +38.7% | ||
| VCELVericel | 0.15% | $42.97 | +4.96% | +19.3% | ||
| SMMTSummit Therapeutics | 0.15% | $15.55 | -1.77% | -11.1% | ||
| DYNDyne Therapeutics | 0.15% | $15.77 | -1.87% | -19.4% | ||
| IRONDisc Medicine | 0.15% | $75.03 | -1.28% | -5.5% | ||
| AGIOAgios Pharmaceuticals | 0.15% | $37.19 | +0.03% | +36.6% | ||
| ZYMEZymeworks | 0.14% | $28.44 | +1.16% | +8.0% | ||
| ELVNEnliven Therapeutics | 0.14% | $41.93 | +0.26% | +172.3% | ||
| AUPHAurinia Pharmaceuticals | 0.14% | $17.33 | +2.54% | +8.7% | ||
| BHVNBiohaven | 0.13% | $14.69 | +25.02% | +30.1% | ||
| SRPTSarepta Therapeutics | 0.13% | $18.18 | -2.05% | -15.5% | ||
| XNCRXencor | 0.13% | $25.84 | +2.70% | +68.8% | ||
| VERAVera Therapeutics | 0.12% | $29.05 | -6.89% | -42.6% |
Estimated portfolio characteristics#
P/B
6.6
weighted
Earnings growth
-232.5%
aggregate TTM, YoY
Estimated by our own bottom-up analysis of the fund’s SEC-filed holdings, covering 87% of portfolio weight (50% carries a valid trailing P/E). Funds publish similar figures on their own sites; ours are recomputed daily from public data.
Methodology#
Holdings and weights are sourced from the fund’s portfolio as disclosed to the SEC on Form N-PORT — a public filing. Portfolio filings are quarterly (public ~60 days after quarter end), so we anchor on the latest one and roll each weight forward daily by that holding’s price move, keeping the numbers current between filings; positions in stocks ChartRow doesn’t track carry their filed weight unchanged and show “—” where we have no data. Returns are total returns (dividends reinvested). One row per company, not per ticker: when a fund holds more than one share class of the same company (Alphabet’s GOOGL and GOOG, for example), we combine them into a single row whose weight is the sum of its classes. Past performance does not predict future returns; not investment advice.
FAQ#
- What are the top 10 holdings of IBB?
- IBB's top 10 holdings are Amgen Inc. (AMGN), 8.8%; Vertex Pharmaceuticals Incorporated (VRTX), 7.8%; Gilead Sciences Inc. (GILD), 7.7%; Regeneron Pharmaceuticals Inc. (REGN), 5.8%; Moderna Inc. (MRNA), 5.1%; Natera Inc. (NTRA), 3.9%; Argenx SE, 3.4%; Illumina Inc. (ILMN), 2.9%; Biogen Inc. (BIIB), 2.6%; Revolution Medicines Inc. (RVMD), 2.5% — together about 50% of the fund, per its Jun 30, 2026 SEC filing with weights rolled forward to today.
- How many holdings does IBB have?
- iShares Biotechnology ETF (IBB) held 247 positions as of Jun 30, 2026, the date of its latest public portfolio report to the SEC.
- How current are IBB's holdings?
- The list of holdings is as of Jun 30, 2026. Funds report their full portfolio to the SEC on Form N-PORT, and the report for the last month of each fiscal quarter becomes public about 60 days after that month ends, so the newest public portfolio is always two to five months old. Between reports ChartRow updates each weight daily by that holding's price move, so the weights estimate today; the positions themselves change only when the next report is published. A fund's own website may list more recent holdings.
- Is ChartRow affiliated with IBB or BlackRock?
- No. ChartRow is independent and is not affiliated with, sponsored by, or endorsed by BlackRock or iShares Biotechnology ETF. Everything on this page is derived independently from the fund's public SEC filings; fund names and trademarks belong to their owners. For information only — not investment advice.